Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone513-579-9911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$704.59 million
Profitability
Miscellaneous
Employees2,500
Next Earnings Date4/29/2019 (Estimated)
OptionableOptionable
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) announced its quarterly earnings results on Monday, February, 25th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.07. The company had revenue of $192.12 million for the quarter, compared to analysts' expectations of $184.66 million. Medpace had a net margin of 11.27% and a return on equity of 17.66%. Medpace's quarterly revenue was up 70.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.39 earnings per share. View Medpace's Earnings History.
When is Medpace's next earnings date?
What guidance has Medpace issued on next quarter's earnings?
Medpace issued an update on its FY19 earnings guidance on Monday, February, 25th. The company provided EPS guidance of $2.58-2.69 for the period, compared to the Thomson Reuters consensus estimate of $2.97. The company issued revenue guidance of $783-807 million, compared to the consensus revenue estimate of $799.26 million.Medpace also updated its FY 2019 guidance to $2.58-2.69 EPS.
What price target have analysts set for MEDP?
5 brokerages have issued 12-month target prices for Medpace's stock. Their predictions range from $35.00 to $63.00. On average, they anticipate Medpace's stock price to reach $46.75 in the next twelve months. This suggests that the stock has a possible downside of 15.5%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.
Has Medpace been receiving favorable news coverage?
Press coverage about MEDP stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a media sentiment score of 1.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Neurocrine Biosciences (NBIX), SAGE Therapeutics (SAGE), NMC HEALTH PLC/ADR (NMHLY), Exelixis (EXEL), WILLIAM DEMANT/ADR (WILYY), BIO-TECHNE (TECH), Eurofins Scientific (ERFSF), Recordati (RCDTF), Loxo Oncology (LOXO), Marina Biotech (MRNA), Icon (ICLR), Carl Zeiss Meditec (AFX), Masimo (MASI), Hill-Rom (HRC) and Charles River Laboratories Intl. (CRL).
What other stocks do shareholders of Medpace own?
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.68%), Pendal Group Ltd (4.48%), Acadian Asset Management LLC (3.81%), Bank of New York Mellon Corp (2.12%), Dimensional Fund Advisors LP (1.42%) and Dimensional Fund Advisors LP (1.42%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, D. E. Shaw & Co. Inc., Acadian Asset Management LLC, Bernzott Capital Advisors, Penserra Capital Management LLC, First Trust Advisors LP, Thrivent Financial for Lutherans and GSA Capital Partners LLP. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Pendal Group Ltd, Bank of New York Mellon Corp, PNC Financial Services Group Inc., Principal Financial Group Inc., Ranger Investment Management L.P., MERIAN GLOBAL INVESTORS UK Ltd and Gotham Asset Management LLC. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $55.33.
How big of a company is Medpace?
Medpace has a market capitalization of $1.97 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,500 workers across the globe.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
